Boehringer Ingelheim: beer on stage at ERS symposium led to Clause 9.1 breach (AUTH/2731/9/14)

📅 2014 | 🖉 Dr Anzal Qurbain
📊

Key facts

CaseAUTH/2731/9/14
ComplainantPulmonologist (working in Germany)
CompanyBoehringer Ingelheim
EventScientific satellite symposium at ERS Congress, Munich
Session title (as advertised)“Slowing disease progression in IPF: New evidence From Phase III clinical trials”
Main issueBeer appeared to be consumed on stage; overall impression deemed unacceptable/inappropriate subsistence
UK involvement2 of 4 speakers were UK health professionals; 63 UK respiratory health professionals sponsored to attend ERS Congress
Applicable Code year2014
Clauses considered by Authority7.2, 9.1, 12.1
Breach(es)Clause 9.1
SanctionsUndertaking received; additional sanctions not stated
Complaint received16 September 2014
Case completed19 January 2015
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A pulmonologist in Germany complained about a Boehringer Ingelheim scientific satellite symposium at the European Respiratory Society (ERS) Congress in Munich.
  • The session was advertised in the official programme as “Slowing disease progression in IPF: New evidence From Phase III clinical trials”.
  • The complainant alleged that speakers were allowed to drink beer on the main stage and that one speaker was dressed in lederhosen, which he considered inappropriate given IPF is a serious, fatal condition.
  • Two of the four speakers were UK health professionals; Boehringer Ingelheim had also sponsored 63 UK respiratory health professionals to attend the ERS Congress.
  • Boehringer Ingelheim argued the symposium was organised by its German parent (Boehringer Ingelheim GmbH Co KG) and was outside the scope of the UK Code; BI UK said its role was limited to approving honoraria/subsistence/hospitality for UK speakers via a clearing house system.
  • The Panel considered the Code applied to promotion to UK health professionals at international meetings outside the UK and that UK companies are responsible for relevant acts/omissions of overseas affiliates within scope.
  • The Panel reviewed a photograph showing a pint glass appearing to contain beer on the stage near a UK speaker and concluded the overall impression was unacceptable and the subsistence inappropriate.
⚖️

Outcome

  • Breach found: Clause 9.1.
  • No breach findings were reported for Clauses 7.2 or 12.1 (these were queried by the Authority but were not ruled as breached in the published decision).
  • No appeal.
  • Undertaking received.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training